PT  - JOURNAL ARTICLE
AU  - Di Domenico, Laura
AU  - Pullano, Giulia
AU  - Sabbatini, Chiara E.
AU  - Boëlle, Pierre-Yves
AU  - Colizza, Vittoria
TI  - Modelling safe protocols for reopening schools during the COVID-19 pandemic in France
AID  - 10.1101/2020.05.08.20095521
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.05.08.20095521
4099  - http://medrxiv.org/content/early/2021/01/14/2020.05.08.20095521.short
4100  - http://medrxiv.org/content/early/2021/01/14/2020.05.08.20095521.full
AB  - As countries in Europe implement strategies to control COVID-19 pandemic, different options are chosen regarding schools. Through a stochastic age-structured transmission model calibrated to the observed epidemic in Île-de-France in the first wave, we explored scenarios of partial, progressive, or full school reopening. Given the uncertainty on children’s role, we found that reopening schools after lockdown may increase COVID-19 cases, yet protocols exist that maintain the epidemic controlled. Under a scenario with stable epidemic activity if schools were closed, reopening pre-schools and primary schools would lead up to 76% [67, 84]% occupation of ICU beds if no other school level reopened, or if middle and high schools reopened later. Immediately reopening all school levels may overwhelm the ICU system. Priority should be given to pre- and primary schools allowing younger children to resume learning and development, whereas full attendance in middle and high schools is not recommended for stable or increasing epidemic activity. Large-scale test and trace are required to maintain the epidemic under control. Ex-post assessment shows that progressive reopening of schools, limited attendance, and strong adoption of preventive measures contributed to a decreasing epidemic after lifting the first lockdown.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study is partially funded by: ANR projects SPHINX (ANR-17-CE36-0008-05) and DATAREDUX (ANR-19-CE46-0008-03); EU H2020 grants RECOVER (H2020- 101003589) and MOOD (H2020-874850); REACTing COVID-19 modeling grant; INSERM-INRIA partnership on data science and public health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:I confirm all relevant ethical guidelines have been followed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available at the references cited.